122 related articles for article (PubMed ID: 20006500)
1. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500
[TBL] [Abstract][Full Text] [Related]
2. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.
Lin H; Yamashita DS; Zeng J; Xie R; Verma S; Luengo JI; Rhodes N; Zhang S; Robell KA; Choudhry AE; Lai Z; Kumar R; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):679-83. PubMed ID: 20005102
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt.
Ko JH; Yeon SW; Ryu JS; Kim TY; Song EH; You HJ; Park RE; Ryu CK
Bioorg Med Chem Lett; 2006 Dec; 16(23):6001-5. PubMed ID: 16990001
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
5. New thiazole carboxamides as potent inhibitors of Akt kinases.
Chang S; Zhang Z; Zhuang X; Luo J; Cao X; Li H; Tu Z; Lu X; Ren X; Ding K
Bioorg Med Chem Lett; 2012 Jan; 22(2):1208-12. PubMed ID: 22172705
[TBL] [Abstract][Full Text] [Related]
6. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors.
Ioannidis S; Lamb ML; Almeida L; Guan H; Peng B; Bebernitz G; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1669-73. PubMed ID: 20144546
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design.
Dong X; Zhan W; Zhao M; Che J; Dai X; Wu Y; Xu L; Zhou Y; Zhao Y; Tian T; Cheng G; Jin Z; Li J; Shao Y; He Q; Yang B; Weng Q; Hu Y
J Med Chem; 2019 Aug; 62(15):7264-7288. PubMed ID: 31298542
[TBL] [Abstract][Full Text] [Related]
8. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened.
Peukert S; He F; Dai M; Zhang R; Sun Y; Miller-Moslin K; McEwan M; Lagu B; Wang K; Yusuff N; Bourret A; Ramamurthy A; Maniara W; Amaral A; Vattay A; Wang A; Guo R; Yuan J; Green J; Williams J; Buonamici S; Kelleher JF; Dorsch M
ChemMedChem; 2013 Aug; 8(8):1261-5. PubMed ID: 23821351
[No Abstract] [Full Text] [Related]
9. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.
Kettle JG; Brown S; Crafter C; Davies BR; Dudley P; Fairley G; Faulder P; Fillery S; Greenwood H; Hawkins J; James M; Johnson K; Lane CD; Pass M; Pink JH; Plant H; Cosulich SC
J Med Chem; 2012 Feb; 55(3):1261-73. PubMed ID: 22248236
[TBL] [Abstract][Full Text] [Related]
10. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Siu T; Li Y; Nagasawa J; Liang J; Tehrani L; Chua P; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4191-4. PubMed ID: 18550373
[TBL] [Abstract][Full Text] [Related]
11. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
13. Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
Bilodeau MT; Balitza AE; Koester TJ; Manley PJ; Rodman LD; Buser-Doepner C; Coll KE; Fernandes C; Gibbs JB; Heimbrook DC; Huckle WR; Kohl N; Lynch JJ; Mao X; McFall RC; McLoughlin D; Miller-Stein CM; Rickert KW; Sepp-Lorenzino L; Shipman JM; Subramanian R; Thomas KA; Wong BK; Yu S; Hartman GD
J Med Chem; 2004 Dec; 47(25):6363-72. PubMed ID: 15566305
[TBL] [Abstract][Full Text] [Related]
14. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
Hartnett JC; Barnett SF; Bilodeau MT; Defeo-Jones D; Hartman GD; Huber HE; Jones RE; Kral AM; Robinson RG; Wu Z
Bioorg Med Chem Lett; 2008 Mar; 18(6):2194-7. PubMed ID: 18294842
[TBL] [Abstract][Full Text] [Related]
15. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
Kendall JD; Giddens AC; Tsang KY; Frédérick R; Marshall ES; Singh R; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):58-68. PubMed ID: 22177407
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
17. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
18. Rapid assembly of diverse and potent allosteric Akt inhibitors.
Wu Z; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Kohl NE; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2008 Mar; 18(6):2211-4. PubMed ID: 18296048
[TBL] [Abstract][Full Text] [Related]
19. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
Zhu GD; Gandhi VB; Gong J; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Jarvis K; Park C; Jong RD; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jul; 16(13):3424-9. PubMed ID: 16644221
[TBL] [Abstract][Full Text] [Related]
20. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]